New York University · Microbiology & ImmunologyAndrogen Antagonist Lab
Michael J. Garabedian · New York, New York
Research Focus
Michael J. Garabedian's lab focuses on developing innovative treatments for prostate cancer, particularly in cases where standard anti-androgen therapies fail. They are exploring a new class of molecules called peptoid conjugates, designed to effectively antagonize the androgen receptor and stop tumor growth. In addition to their anti-cancer properties, these peptoids may also stimulate the immune system to enhance cancer treatment effectiveness.
prostate cancerandrogen receptorpeptoid conjugatesimmunotherapydrug resistancecytotoxic T cellgene expressionmolecular interactionxenograftsChIP-seq
Research Aims
5AIM 01Develop peptoid conjugates to inhibit androgen receptor activity in prostate cancer cells.
AIM 02Evaluate the potential of peptoid conjugates to enhance immune responses against tumors.
AIM 03Identify target genes of peptoid conjugates using ChIP-seq and RNA-seq.
AIM 04Characterize the molecular interaction between peptoid conjugates and the androgen receptor.
AIM 05Investigate the use of peptoid conjugates to sensitize tumors to immune checkpoint blockade therapies.
Skills the Lab Values
X-ray crystallographyRNA sequencingChIP-seqcell culturexenograft modelsflow cytometryimmunohistochemistrydata analysiscompound synthesisprotein expression
Output against the department
Publications249top 23% of dept.110th of 486
this lab
most publishedleast published
Citations12ktop 30% of dept.144th of 486
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.